YURAK YETISHMOVCHILIGI VA TEMIR TANQISLIGI BO‘LGAN BEMORLARDA INTRAVENOZ TEMIR PREPARATLARINI KLINIK NATIJALARGA TA’SIRI
##article.subject##:
yurak yetishmovchiligi, temir tanqisligi, tomir ichiga yuboriladigan temir, karboksimaltozat temiri, klinik natijalar, funksional imkoniyat##article.abstract##
Randomizatsiyalangan, ikki tomonlama ko‘r, platsebo-nazoratli tadqiqotda yurak yetishmovchiligi va temir tanqisligidan aziyat chekayotgan 135 bemorda temir karboksimaltozatining vena ichiga yuborilishi ikkilamchi klinik natijalarga ta’siri baholandi. Ishtirokchilar ikki guruhga bo‘lindi: asosiy (n = 68) va nazorat guruhi (n = 67), kuzatuv muddati esa 24 hafta edi. Kompozit yakuniy nuqta quyidagilarni o‘z ichiga oldi: NYHA funksional klassidagi o‘zgarishlar, KCCQ so‘rovnomasining ballari, NT-proBNP darajasi, 6 daqiqalik yurish masofasi (6MWD) va yurak yetishmovchiligi tufayli shifoxonaga yotqizish chastotasi.Vena ichiga temir olgan kohortada quyidagi parametrlar bo‘yicha platsebo guruhi bilan solishtirganda statistik jihatdan ahamiyatli yaxshilanish kuzatildi: NYHA funksional klassi (≥1 klassga yaxshilanish: 62% ga qarshi 31%, p < 0,001), KCCQ ko‘rsatkichlari (+18,6 ga qarshi +6,2, p < 0,001), NT-proBNP darajalari (—420 ga qarshi —110 pg/ml, p < 0,001), 6 daqiqalik yurish masofasi (+64 ga qarshi +24 m, p < 0,001) hamda shifoxonaga yotqizish darajasi (13,2% ga qarshi 28,4%, p = 0,032).Vena ichiga temir yuborilishi yurak yetishmovchiligi, pasaygan ejeksiya fraksiyasi va temir tanqisligiga ega bo‘lgan bemorlarning klinik ahvolini, funksional imkoniyatlarini hamda biologik markerlarini sezilarli darajada yaxshilaydi, shuningdek, shifoxonaga yotqizishlar sonini kamaytirishga yordam beradi. Dori yaxshi ko‘tarilgan, guruhlar o‘rtasida nojo‘ya ta’sirlar bo‘yicha jiddiy farqlar kuzatilmadi.
Библиографические ссылки
Jankowska, E.A. Iron deficiency: an ominous sign in patients with systolic chronic heart failure / E.A. Jankowska, P. Rozentryt, A. Witkowska [et al.] // European Heart Journal. – 2010. – Vol. 31, № 15. – P. 1872–1880. – DOI: 10.1093/eurheartj/ehq158.
Anand, I.S. Anemia and Iron Deficiency in Heart Failure: Current Concepts and Emerging Therapies / I.S. Anand, P. Gupta // Circulation. – 2018. – Vol. 138, № 1. – P. 80–98. – DOI: 10.1161/CIRCULATIONAHA.118.030099.
Von Haehling, S. Iron deficiency and cardiovascular disease / S. von Haehling, E.A. Jankowska, D.J. van Veldhuisen [et al.] // Nature Reviews Cardiology. – 2015. – Vol. 12, № 11. – P. 659–669. – DOI: 10.1038/nrcardio.2015.109.
Anker, S.D. Ferric carboxymaltose in patients with heart failure and iron deficiency / S.D. Anker, J. Comin Colet, G. Filippatos [et al.] // New England Journal of Medicine. – 2009. – Vol. 361, № 25. – P. 2436–2448. – DOI: 10.1056/NEJMoa0908355.
Ponikowski, P. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency / P. Ponikowski, D.J. van Veldhuisen, J. Comin-Colet [et al.] // European Heart Journal. – 2015. – Vol. 36, № 11. – P. 657–668. – DOI: 10.1093/eurheartj/ehu385.
Ponikowski, P. Ferric Carboxymaltose for Iron Deficiency at Discharge after Acute Heart Failure: A Multicentre, Double-Blind, Randomised, Controlled Trial / P. Ponikowski, B.A. Kirwan, S.D. Anker [et al.] // The Lancet. – 2020. – Vol. 396, № 10266. – P. 1895–1904. – DOI: 10.1016/S0140-6736(20)32339-4.
McDonagh, T.A. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure / T.A. McDonagh, M. Metra, M. Adamo [et al.] // European Heart Journal. – 2021. – Vol. 42, № 36. – P. 3599–3726. – DOI: 10.1093/eurheartj/ehab368.
